Under tamoxifen treatment‐induced hypoxic condition, CAIX was specifically increased in ER+ cells, rendering that targeting CAIX would be a promising strategy to predict tamoxifen resistance in ER+ breast cancer therapy. The gene discussed is CA9; the disease is breast cancer.